Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer

Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer

The following license files are associated with this item:

This item appears in the following Collection(s)

Attribution 3.0 United States Except where otherwise noted, this item's license is described as Attribution 3.0 United States

Search Repository


My Account

Statistics